What are your top takeaways in GU Cancers from ASCO 2024?

In terms of practice-changing/informing datasets newly presented at ASCO 2024, here are my top 5:

1. Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy. LBA12004, Stish et al. This 88-patient randomized phase 2 trial clearly demonstrates the efficacy of low and high-dose oxybutynin 2.5-5 mg 2x/day for the control of hot flashes during ADT, showing clear reduction...

1. @Dr. First Last: EV-302 PRO/QoL data
2. @Dr. First Last: Dose exposure and association with ORR with EV monotherapy
3. @Dr. First Last: CheckMate 901 - characterization of patients with complete response
4. Antonio Cigliola: SURE-01 neoadjuvant sacituzumab in MIBC

My top 3 for prostate cancer were:

1. Abstract 5010: JNJ-69086420 for mCRPC
2. Abstract 5011: ARV-766 for mCRPC
3. Abstract 5012: Tarlatamab for Neuroendocrine Prostate Cancer

1. Abstract 4503, Dr. @Dr. First Last's review of dose received and duration of therapy for EV/pembro in metastatic urothelial ca reassured me that patients do well even with reduced dosing of EV.
   
   
2. Dr. @Dr. First Last's discussion of KIM-1 in response to Dr. Albiges' post hoc analysis of KIM-1 in IMmotion010 was excellent.

PSMAfore presented previously showed (177Lu-PSMA-617) prolonged radiographic progression-free survival vs change of androgen receptor pathway inhibitor (ARPI) in taxane-naïve patients with metastatic castration-resistant prostate cancer. At ASCO, data presented showed 177Lu-PSMA-617 delayed time to worsening in self-reported pain and HRQoL vs change of ARPI in taxane-naïve patients with PSMA-positive mCRPC. There was no difference in survival.

1. KEYNOTE-361 trial, Abstract 4518 - Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.
   -- This is particularly important as it demonstrates (congruent with results from other studies as well) that ctDNA response is an important treatment monitoring tool. Currently (except for prostate cancer with PSA) we only have periodic c...